Mauricio Fernando Silva Almeida Ribeiro, MD
Hematology & Oncology · Tampa, FLNPI 1346027174
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (47.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Springworks Therapeutics, Inc. accounts for 71.6% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $21,757, more than ten times the $146 reported in 2023.
Across 34 payments — averaging $804.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Springworks Therapeutics, Inc.$20K
- Deciphera Pharmaceuticals Inc.$6K
- EMD Serono, Inc.$2K
- Aadi Bioscience, Inc.$146
Across 1 payment — averaging $284.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$284
What the payments were for
- Consulting fees$10,86540%
- Speaking & faculty fees$13,07548%
- Travel & lodging$1,6516%
- Food & beverage$1,5406%
- Gifts$2121%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Springworks Therapeutics, Inc. | 16 | $19,566 |
| Deciphera Pharmaceuticals Inc. | 16 | $5,516 |
| EMD Serono, Inc. | 1 | $2,115 |
| Aadi Bioscience, Inc. | 1 | $146 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OGSIVEO$8,862
- QINLOCK$2,679
- VIMSELTINIB$2,244
- ROMVIMZA$154
- FYARRO$146
How this compares
$27,343 in reported general payments places this provider in the 75th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Imatinib Mesylate | 33 | $107,283 |
| Ondansetron Hcl | 19 | $479 |
| Prochlorperazine Maleate | 11 | $303 |
| Pregabalin | 13 | $241 |
| Oxycodone Hcl | 11 | $216 |
| Dexamethasone | 15 | $149 |
| Tramadol Hcl | 11 | $103 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Tampa
- Damian LaberTampa$753K
- Richard KimTampa$637K
- Ariel Grajales CruzTampa$625K
- Julio ChavezTampa$383K
- David SallmanTampa$285K
- Daniel Kerr IiTampa$193K
- Bijal ShahTampa$150K
- Nikesh ShahTampa$141K
- Kendra SweetTampa$139K
- Hayder SaeedTampa$127K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.